Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 22 chart positions in 22 markets.
By chart position
- 🇬🇧GB · Life Sciences#50100K to 300K
- 🇦🇺AU · Life Sciences#1275K to 30K
- 🇩🇪DE · Life Sciences#1615K to 30K
- 🇯🇵JP · Life Sciences#15100K to 300K
- 🇮🇹IT · Life Sciences#5030K to 100K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
102K to 323K🎙 Daily cadence·223 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
340K to 1.1M🇬🇧28%🇯🇵28%🇮🇹9%+19 more - Active Followers
Loyal subscribers who consistently listen
136K to 430K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 19 epsHosts
Recent guests
Recent episodes
How Sandoz Cut Its Supplier Network by 34%: A Step-by-Step Consolidation Playbook
Jun 25, 2026
Unknown duration
We're joining Life Science Connect. Here's the story...
Jun 23, 2026
Unknown duration
Simtra BioPharma CCO: “Manufacturing in the Region for the Region Is Here to Stay”
Jun 18, 2026
Unknown duration
Closing the Biotech "Valley of Death": The Infrastructure Gap Holding Back Early-Stage Biologics Programs:
Jun 14, 2026
Unknown duration
How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar
Jun 11, 2026
31m 23s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/25/26 |  How Sandoz Cut Its Supplier Network by 34%: A Step-by-Step Consolidation Playbook | At CDMO Live Europe 2026 Maik Talarczyk Head PMO External Supplier Operations, Sandoz, laid out the company’s three-year supplier network consolidation program, detailing a six-step make-vs-buy decision framework that reduced network complexity by 34% against its 2023 baseline.Maik Talarczyk opened with a warning. “The fan is always on – and the shit is always flying.”Sandoz entered 2024 managing approximately 500 finished dose form (FDF) suppliers — a network Talarczyk describes as fragmented and expensive to run. The initial diagnosis was that 20% of suppliers accounted for 80% of sales. But the structural problem ran deeper: commercial and technical operations weren’t talking to each other. Country organizations understood top-line sales and margin. They did not see what was happening in technical operations.Read the full article | — | ||||||
| 6/23/26 |  We're joining Life Science Connect. Here's the story... | "We saw what you guys built and made a decision pretty quickly: we didn't want to compete with that. We wanted to be part of it." Jon Howland, CEO, Life Science ConnectToday we are announcing that PharmaSource, CDMO Live and External Manufacturing Leaders will be joining forces with Life Science Connect to create a new events divison.In this special episode, Luke Bilton sits down with Life Science Connect CEO Jon Howland to talk about what's been going on behind the scenes, and what this new chapter means to biopharma outsourcing media and events.Read more on PharmaSource | — | ||||||
| 6/18/26 |  Simtra BioPharma CCO: “Manufacturing in the Region for the Region Is Here to Stay” | Mike Schaefers, Chief Operating Officer at Simtra BioPharma, outlined what it takes to build durable CDMO partnerships in injectable manufacturing, why regional supply chains have become a permanent feature, and how early-phase collaboration directly shortens time to market. | — | ||||||
| 6/14/26 |  Closing the Biotech "Valley of Death": The Infrastructure Gap Holding Back Early-Stage Biologics Programs: | "The challenge is not getting better biology. It's building a better system to carry the biology forward," says Richard van Rijnsoever.Debby Vermeer and Richard van Rijnsoever are co-founders of ExpediteBio, a Netherlands-based venture focused on accelerating antibody and protein therapeutics from discovery to first-in-human study. Debby also co-leads the biologics workstream at Oncode Accelerator, a national initiative working to accelerate cancer therapy development, e.g., by building infrastructure in the Netherlands.On the PharmaSource podcast, Debby and Richard spoke about the structural reasons biologics programs fail to reach patients, how their ASCEND framework addresses those failures, and what a more functional European biologics ecosystem could look like. Their conversation is a practical guide for biotech CEOs and CMC leaders navigating the most expensive stretch of early-stage drug development.Read more. | — | ||||||
| 6/11/26 |  How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar✨ | regulatory affairspharmaceutical strategy+5 | Manda Pasarkar | SanofiTeva+2 | USEU+2 | regulatory CMCpharmaceutical compliance+5 | — | 31m 23s | |
| 6/8/26 |  The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy✨ | pharmaceutical pricingglobal strategy+4 | Cristoffer FrendesenGil Roth | Dagens PharmaPharma and Biopharma Outsourcing Association+1 | USEurope | MFN pricingtariffs+5 | — | 17m 45s | |
| 6/4/26 |  How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability✨ | vaccine supply chainmanufacturing+4 | Krish RamanathanSavant Ahmed+3 | Gates Medical Research InstituteExela Pharma Sciences+4 | — | vaccine developmentmanufacturing operations+3 | — | 46m 24s | |
| 5/31/26 |  How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization✨ | bioconjugationAI+4 | Christian Seufert | LonzaBASF+2 | — | LonzaCDMO+5 | — | 29m 10s | |
| 5/27/26 |  The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher✨ | strategic partnershipsCDMOs+4 | Kaan Fabian-KekecClarita Havermeier | Simon-KucherPharmaSource | — | CDMOpharma+6 | — | 25m 31s | |
| 5/25/26 |  Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round✨ | biotech financingcapital constraints+3 | Baruch Harris | Pretzel TherapeuticsRome Therapeutics+1 | biotech | biotechfinancing+6 | — | 29m 11s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/18/26 |  Decarbonizing Pharma: Why Green Chemistry Must Lead the Sustainability Agenda✨ | sustainabilitygreen chemistry+3 | Celine ChenDavid Ennis | PharmaBlockAstraZeneca | — | sustainabilitydecarbonization+3 | — | 26m 37s | |
| 5/14/26 |  Kindeva's $200M Sterile Injectable Investment is Raising Compliance Standards✨ | sterile injectablesCDMO services+3 | Tommy Shornak | KindevaAMRI+2 | — | Kindevasterile injectables+3 | — | 17m 20s | |
| 5/11/26 |  How PI Health Sciences Delivers Real-Time Visibility and Scientific Accountability✨ | CDMO selectionscientific accountability+4 | Alessio Piccoli | PI Health SciencesPI Industries+3 | JaipurHyderabad+1 | CDMOCRO+5 | — | 23m 04s | |
| 5/7/26 |  Navigating Chaos: Jan Ramakers on Why the API Market Is Harder to Read Than Ever✨ | API marketoutsourcing+3 | Jan Ramakers | PharmaSourceCDMO+1 | — | API marketpharmaceutical ingredients+4 | — | 34m 11s | |
| 5/3/26 |  How to Manage Molecule Uncertainty: Nick Wigdahl on Portfolio Optimization and Pharma Lifecycle Strategy✨ | molecule uncertaintyportfolio optimization+3 | Nick Wigdahl | PharmaGroRoche+2 | — | molecule uncertaintyportfolio management+3 | — | 22m 01s | |
| 4/30/26 |  IPSC Manufacturing: From Dolly the Sheep to Clinical-Grade Cell Therapies✨ | iPSC manufacturingcell therapies+3 | Stephen Sullivan | iPSC-based cancer vaccineLinville Bio+3 | — | iPSCcell therapy+5 | — | 37m 38s | |
| 4/26/26 |  Agentic AI x Pharma Manufacturing: Interview with Matt Lowe, Chief Strategy Officer, MasterControl✨ | agentic AIpharma manufacturing+4 | Matt Lowe | MasterControlPharmaSource Podcast+1 | — | agentic AIpharma manufacturing+5 | — | 29m 12s | |
| 4/23/26 |  Oral Solid Dosage Manufacturing: Inside Rottendorf Pharma’s Strategic Alliance With Corealis Pharma✨ | oral solid dosagepharmaceutical development+3 | Eike Cordts | Rottendorf PharmaCorealis Pharma | North AmericaGermany+1 | Rottendorf PharmaCorealis Pharma+6 | — | 23m 11s | |
| 4/20/26 |  Combination Product Manufacturing: GLP-1 Hype, Talent Shortages, and the CDMO Shift✨ | combination product manufacturingGLP-1+5 | Steven Kaufman | PharmaSource PodcastLife Science Networks | — | combination devicesfill/finish manufacturing+7 | — | 42m 36s | |
| 4/16/26 |  Novartis on What Great CDMO Partnerships Actually Look Like✨ | CDMO partnershipscontract manufacturing+3 | Isabel FeuersteinMark Schiefermeier | NovartisDS Schaftenau | Austria | CDMOcontract manufacturing+5 | — | 22m 02s | |
| 4/13/26 |  Eramol's Sterile Facility Targets >1% Material Loss for Biotech Clients✨ | sterile injectable manufacturingbiotech challenges+3 | Peter MollisonDavid Cox | EramolEU GMP Annex One | SittingbourneKent | sterile facilitybiotech+3 | — | 20m 07s | |
| 4/9/26 |  Delpharm CEO: Every Day Lost in Clinical Manufacturing Is a Day of Peak Sales Gone Forever✨ | clinical manufacturingpharmaceutical industry+3 | Nicolas Ragot | DelpharmEli Lilly+2 | — | clinical phasepeak sales+3 | — | 16m 44s | |
| 4/6/26 |  The Pharma Direct-to-Consumer Shift: Moving Faster Than Infrastructure Can Handle✨ | pharmaceutical industrydirect-to-consumer+3 | Ryan Kelly | Rx-360Amazon+3 | — | pharmaceuticaldirect-to-consumer+3 | — | 26m 49s | |
| 4/2/26 |  How the BMC Achieves Clinical-to-Commercial Quality Continuity Across Its Biologics CDMO Platform | "Sponsors don't want to know how many SOPs you have on the shelf. They're really looking to see if you have sound judgment to take care of their program." Mohamad Ahmad, Vice President of Quality and Compliance at the Biologics Manufacturing Centre (BMC) Inc., brings extensive quality leadership experience across the pharmaceutical industry. The BMC is a Canadian non-profit CDMO established in response to Canada’s effort to strengthen domestic biologics manufacturing capacity following the pandemic. There, Mohamad oversees quality systems across all biologics manufacturing operations, from early clinical through commercial scale.In this episode of the PharmaSource podcast, Mohamad explains why a risk-based, science-driven approach to quality is the defining factor that separates strong CDMO partners from the rest — and how the BMC has built its quality organization to deliver that across every stage of a program's lifecycle.Read more. | — | ||||||
| 3/30/26 |  Digital Twins in Claude: How BioPharma Can Build Forecast and Supply Models | “The level of comfort with AI use in this space is pretty low right now.” Mike Boyson’s observation cuts to the heart of pharma’s AI dilemma. Hesitation is justified—but it shouldn’t paralyze action. His answer: build practical, compliant digital twins that operators can create in Claude without waiting for IT.Mike is a supply chain and pharmaceutical operations leader with over 20 years of experience spanning CMC strategy, external manufacturing, and digital transformation. He spent more than a decade at Takeda leading oncology and biologics supply chain operations, served as Executive Director of Value Chain Leadership at Moderna, and now advises organizations at Azure Biopharma Consulting on adopting AI-driven solutions.In a recent PharmaSource podcast episode, Mike shares concrete use cases for digital twins, explains how to build them without deep technical expertise, and addresses the GXP compliance, data confidentiality, and human-centered challenges that will define pharma AI adoption.Watch the video to accompany this episode here | — | ||||||
Showing 25 of 241
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
23 placements across 22 markets.
Chart Positions
23 placements across 22 markets.